What is sustaining DES revenue growth above older-generation coronary stent platforms?
Contemporary ultrathin-strut drug-eluting stents — featuring cobalt-chromium or platinum-chromium alloy struts below 80 microns in thickness, biodegradable polymer drug carrier systems that resorb within 3 to 6 months of implantation eliminating chronic polymer inflammation, and everolimus or zotarolimus antiproliferative drug elution — have demonstrated MACE rates and stent thrombosis frequencies at 5-year follow-up that approach the event rates of bare metal stents without the target lesion revascularisation penalties of older thick-strut DES platforms. Ultrathin biodegradable polymer DES platforms from Orsiro, Synergy, Ultimaster, and Resolute Onyx are sustaining premium DES pricing above older permanent polymer platforms.

How is the EVAR stent graft market evolving with complex anatomy endovascular repair?
Conventional infrarenal EVAR stent grafts require an adequate proximal aortic neck length and morphology for seal zone formation — excluding the substantial proportion of aortic aneurysm patients with short, angulated, or calcified necks. Fenestrated and branched endovascular aneurysm repair devices, customised to individual patient aortic anatomy with fenestrations or branches accommodating visceral and renal artery origins, extend EVAR eligibility to the complex anatomy patient population previously requiring open surgical repair or excluded from treatment due to prohibitive surgical risk. The fenestrated EVAR addressable market represents a large untreated aneurysm population and sustains the highest revenue per device episode within the aortic stent graft category.

What advances in BTK peripheral stenting are addressing below-the-knee revascularisation in CLI?
Below-the-knee peripheral artery disease in critical limb-threatening ischaemia presents the most challenging peripheral vascular intervention indication due to small tibial and peroneal vessel calibres below 3 mm, diffuse multilevel calcified disease, and historically poor stent durability in the low-flow, high-resistance BTK arterial segment. Drug-eluting BTK stents including cobalt-chromium sirolimus-eluting designs specifically engineered for BTK calibre vessels, drug-coated balloons with antiproliferative paclitaxel or sirolimus coating enabling drug delivery without permanent stent implantation, and absorbable scaffold technologies designed for BTK anatomy are in various stages of clinical validation and early commercial availability across European markets.

How is carotid artery stenting evolving with embolic protection and dual-layer mesh stent designs?
Carotid artery stenting for symptomatic internal carotid artery stenosis has historically been associated with a higher periprocedural stroke risk compared to carotid endarterectomy in lower-surgical-risk patients, attributed to periprocedural plaque embolisation during stent delivery across vulnerable carotid atherosclerotic plaque. Dual-layer mesh carotid stents — featuring an inner fine-mesh layer with a pore size below the threshold for plaque extrusion through stent struts — have demonstrated reduction in periprocedural neurological events versus conventional open-cell carotid stents in prospective registries and are reshaping the carotid stenting risk-benefit balance relative to surgical endarterectomy.

What is sustaining demand for TEVAR stent grafts in thoracic aortic disease management?
Thoracic endovascular aortic repair for descending thoracic aortic aneurysm, complicated type B aortic dissection, traumatic aortic transection, and penetrating aortic ulcer has replaced open surgical repair as the preferred treatment modality at experienced aortic centres for suitable anatomy, driven by substantially lower 30-day mortality and morbidity versus open thoracic aortic surgery. Iterative TEVAR stent graft design evolution providing improved conformability to the transverse arch anatomy, extended seal zone lengths for short landing zone anatomies, and fenestrated or branched designs for arch vessel inclusion are expanding the proportion of thoracic aortic pathology addressable by TEVAR.

Which cardiovascular stent segments are growing fastest?
Drug-eluting BTK peripheral stents and drug-coated balloons for critical limb-threatening ischaemia, fenestrated and branched EVAR for complex aortic aneurysm anatomy, ultrathin biodegradable polymer DES innovation sustaining coronary stent premium pricing, and dual-layer mesh carotid stents improving carotid artery stenting neurological safety are the four fastest-growing cardiovascular stent segments.